© Reuters. FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) – Drugmaker AstraZeneca (NASDAQ:) said on Thursday it will acquire rare endocrine diseases-focused firm Amolyt Pharma for $1.05 billion in cash, in a bid to boost its rare diseases portfolio.
